FCGR2A
FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
Overview
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Trastuzumab.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
- 1 · What it is
FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
- 2 · What goes wrong in cancer
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor.
- 3 · How drugs use it
No product in this corpus aims at FCGR2A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:3616 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P12318 (protein name, function text, keywords and locations (REST API)); CIViC gene FCGR2A (2 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, HER2 Positive Breast Cancer (GraphQL API, CC0))
Biology
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonised antigens. Location: Cell membrane (UniProt). Locus 1q23.3 (HGNC).
- Breast cancer: CIViC evidence names this disease
- HER2-positive breast cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FCGR2A" OR ABSTRACT:"FCGR2A" OR TITLE:"Fc gamma receptor IIa" OR ABSTRACT:"Fc gamma receptor IIa" OR TITLE:"Low affinity immunoglobulin gamma Fc region receptor II-a" OR ABSTRACT:"Low affinity immunoglobulin gamma Fc region receptor II-a" OR TITLE:"CD32" OR ABSTRACT:"CD32" OR TITLE:"CD32A" OR ABSTRACT:"CD32A" OR TITLE:"IGFR2" OR ABSTRACT:"IGFR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FCGR2A, not a curated reading list.